Biotron Ltd
Biotron Advances Hepatitis B Program with Strong Clinical Results Across Key HBV Markers
Biotron (ASX: BIT) has reported a major step forward in its Hepatitis B Virus drug development program, confirming robust antiviral activity for its lead compound BIT-HBV001 across two established mouse models and multiple in vitro assays.
Biotron Announces $2.5 Million Capital Raising to Fund Sedarex Acquisition
Biotron (ASX: BIT) has announced the acquisition of unlisted company Sedarex Limited, the owner of SedRx — a patented next-generation general anaesthetic — alongside a $2.5 million capital raising to fund the transaction and advance development programs. The acquisition delivers Biotron a late-stage clinical asset supported by US Food and Drug Administration (FDA) and European Medicines […]
Biotron’s Phase 2 trial confirms BIT225 HIV treatment potential
Biotron (ASX: BIT) has received further indications that its lead antiviral drug BIT225 is a potential candidate for the treatment of issues related to HIV. The company has informed shareholders that preliminary analyses of data from a Phase 2 clinical trial of BIT225-011 suggest that the primary objectives of the test program have been met. […]
Biotron buoyed by early trial success of BIT225 HIV-1 antiviral drug
Biotron (ASX: BIT) has obtained promising early results from a phase 2 clinical trial of the company’s lead antiviral drug BIT225. Preliminary analysis of trial data indicates BIT225 is having a unique effect beyond that seen with the current standard. It has also been assessed that the primary objectives of the trial have been met, […]